Erzol-D Capsule SR is a combination medication containing Domperidone 30 mg and Rabeprazole 20 mg, formulated for sustained release to provide effective management of gastrointestinal disorders. Domperidone is a peripheral dopamine D2 receptor antagonist that enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and reducing symptoms such as nausea, vomiting, and bloating. Rabeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, leading to prolonged reduction in gastric acidity. The combination of these two agents is particularly beneficial in treating conditions like gastroesophageal reflux disease (GERD), erosive esophagitis, and functional dyspepsia, where both acid suppression and improved motility are desired. Erzol-D Capsule SR is indicated for patients experiencing upper gastrointestinal symptoms related to acid reflux, delayed gastric emptying, or Helicobacter pylori-associated gastritis when combined with appropriate antimicrobial therapy. The sustained-release formulation ensures a steady plasma concentration, enhancing therapeutic efficacy and patient compliance. It should be used under medical supervision, considering contraindications such as hypersensitivity to components, and potential interactions with other medications.